FDA 483 OBSERVATION · #3 OF 1,945 MOST-CITED
Lack of or inadequate complaint procedures
FDA cited this observation 1,775 times across 1,594 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
21 CFR 820.198 (Complaint files) is a Quality System Regulation section; since QMSR took effect on 2 February 2026 FDA inspects this as “Complaint Handling”: 21 CFR 820.10(b)(3)–(4) and 820.35, and ISO 13485 clauses 8.2.2 and 8.2.3 (CP 7382.850 Attachment A).
The firm lacked adequate written procedures for receiving, reviewing, and evaluating complaints, or did not follow them — including failing to decide whether each complaint needed investigation and, for devices, whether it was reportable to FDA as an MDR.
Why FDA writes it — Complaints are the firm’s early-warning system for field failures. A weak complaint-handling process means real product problems go uninvestigated, trends go unseen, and reportable events are never reported — which is why FDA treats it as a high-signal finding.
- Establish a formally designated unit and a written procedure that ensures all complaints are processed uniformly and in a timely manner, and that oral complaints are documented.
- Require a documented decision on whether each complaint warrants investigation — and if not, record the reason and who made the call.
- For devices, build the MDR reportability decision into the complaint workflow so events meeting 21 CFR 803 criteria are captured and reported on time.
- Trend complaints to detect signals a single record would miss, and feed confirmed problems into CAPA.
- Complaints handled ad hoc by whoever answers the phone, with no consistent intake, evaluation, or reportability screen.
- No linkage between complaint handling and CAPA/MDR, so individually “minor” complaints never aggregate into an investigated trend.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.1× the rate of the average FDA-cited firm (8.9% vs 7.8%), across 1,594 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been established.
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →